Tongling

Researchers are conducting a prospective observational cohort study to compare the occurrence of gastric cancer and the progression of precancerous stomach lesions among groups with different Helicobacter pylori (Hp) single nucleotide polymorphism (SNP) subtypes. The study focuses on people who initially have a negative gastric endoscopy and distinguishes between those carrying high-risk Hp SNP subtypes and those with non-high-risk subtypes. The main goal is to assess differences in gastric cancer incidence during follow-up, as well as to observe how precancerous lesions develop over time in these groups. The study involves following asymptomatic individuals who carry either high-risk or non-high-risk Hp SNP subtypes. Participants will be observed over a 3-year period without any active intervention, with researchers monitoring the incidence of gastric cancer and changes in gastric precancerous lesions such as atrophic gastritis and intestinal metaplasia. The study also aims to explore how factors like age, gender, diet, smoking, alcohol use, and family history may influence the risk associated with these Hp subtypes. During the study, participants will undergo baseline and follow-up examinations, including gastric endoscopy, to track the development of gastric cancer and precancerous changes. Researchers will collect data on various risk factors and monitor participants for 3 years from enrollment to measure differences in cancer incidence across the groups. The study excludes those with prior gastric cancer or certain health conditions that could limit participation or survival, ensuring a focused evaluation of risks in this population.

Researchers are establishing a standardized clinical information database for liver cancer patients through a collaborative effort led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China (USTC). This database aims to support high-quality real-world clinical studies and research on hepatocellular carcinoma and related liver cancers. Participants may receive routine treatments such as surgical operations including resection, ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). They might also be treated with various anti-tumor drugs including immunologic, targeted, and chemotherapy medications. Treatments and clinical data are collected to enrich the database for future research. During the study, participants will provide blood samples and postoperative pathology residual samples and will be followed over time to monitor their health and treatment outcomes. The primary outcome measured is overall survival over 10 years. Participants must be willing to comply with follow-up visits and provide informed consent, ensuring comprehensive data collection for long-term analysis.

Researchers are evaluating the use of fecal Helicobacter pylori gastric cancer susceptibility testing combined with a gastric cancer risk questionnaire to improve early detection of gastric cancer. This prospective study aims to determine whether either method alone or together can help diagnose gastric cancer earlier in adults aged 40 and older. The study will be conducted in selected communities within Tongling City, recruiting between 10,000 and 15,000 residents. Participants will provide stool samples for fecal H. pylori gastric cancer susceptibility gene testing and complete a detailed gastric cancer risk questionnaire during initial screening. Those who test positive on either the genetic test or questionnaire will be referred for confirmatory diagnosis using fiberoptic endoscopy and pathological biopsy. Screening-positive individuals without a gastric cancer diagnosis in the first year will enter an annual follow-up program. Residual stool samples will be stored for future biomarker research. Throughout the study, trained investigators will conduct face-to-face interviews and collect samples. Researchers will measure the sensitivity and specificity of the fecal H. pylori test and questionnaire over a two-year period to assess their effectiveness for early gastric cancer detection. The study includes ongoing monitoring, diagnostic follow-up, and biobanking to support long-term research and improve screening methods.

Researchers are evaluating a new multi-target fecal DNA test combined with a gastric cancer risk questionnaire to improve early detection of gastric cancer. This prospective study involves residents from selected communities in Tongling City, aiming to recruit between 10,000 and 15,000 participants aged 40 years and older. The study focuses on assessing the sensitivity and specificity of the fecal DNA test and questionnaire over a two-year period to see if they can help identify gastric cancer earlier. All participants will provide a stool sample for the multi-target DNA analysis, which includes Helicobacter pylori gene detection and fecal methylated DNA markers. They will also complete a detailed gastric cancer risk questionnaire during face-to-face interviews. Those who test positive on the fecal DNA test or are identified as high-risk by the questionnaire will be referred for further diagnostic evaluation, including fiberoptic endoscopy and pathological biopsy. Participants who do not receive a gastric cancer diagnosis after the first year of screening will enter an annual follow-up program. Additionally, leftover stool samples will be stored for future biomarker research. Throughout the study, participants will be monitored through initial screening, diagnostic workup if needed, and follow-up visits. Researchers will collect stool samples, conduct questionnaires, perform endoscopies and biopsies for those at high risk, and track outcomes for up to two years. The main outcomes measured are the accuracy of the fecal DNA test and questionnaire in detecting gastric cancer. The study emphasizes safety by excluding individuals with contraindications to endoscopy and those with serious health conditions that prevent long-term follow-up.

Researchers are investigating the safety and effectiveness of remote ischemic conditioning (RIC) in patients with acute ischemic stroke caused by large vessel blockage in the brain. While endovascular thrombectomy is effective in reopening blocked vessels, many patients still suffer poor outcomes due to brain tissue damage during and after the procedure. The study aims to see if RIC, a noninvasive therapy involving brief cycles of arm blood flow restriction, can protect the brain and improve recovery in these patients. The study compares two durations of remote ischemic conditioning: one lasting 14 days and another lasting 30 days after mechanical thrombectomy. RIC is performed using an automatic device that inflates and deflates a cuff on the upper arm, with five cycles of 5-minute inflation and 5-minute deflation. This procedure is done once before thrombectomy and then twice daily during the assigned post-thrombectomy period. All patients also receive best medical management according to guidelines. Mechanical thrombectomy is done following standard practices to reopen blocked vessels safely. Participants will be monitored for 90 days after their stroke to assess recovery and safety. The main measure is the proportion of patients who achieve a good functional outcome, defined as a modified Rankin Scale score of 0 to 2 at 90 days. Throughout the study, medical evaluations, imaging, and clinical assessments will be conducted to track progress and any side effects. The study also explores how the length of RIC treatment affects patient outcomes, aiming to find the best approach to protect the brain after stroke treatment.